Reports
Subscribe to
our newsletters!
Showing 61–80 of 83 resultsSorted by latest
- Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
- This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies and of selected biosimilars in the calendar year 2019€ 90.00
- This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.€ 250.00
- This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00
- Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructsOriginal price was: € 3150.00.€ 2500.00Current price is: € 2500.00.
- This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
- This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.€ 50.00
- This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.€ 2350.00
- This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)€ 150.00
- This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.€ 50.00
- This report provides a compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies in the calendar year 2018.€ 80.00
- These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.Original price was: € 4450.00.€ 2670.00Current price is: € 2670.00.
- This report informs about the competitive field of novel DNA vaccines in clinical development for prevention and/or treatment of cancer, infectious and other diseases.€ 400.00
- This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.€ 75.00